ArticleFrontiers in medicine2026
CD161 and LLT1 expression in immune cell populations of Hodgkin lymphoma tumor microenvironment.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hodgkin lymphoma (HL) tumor microenvironment (TME) is composed of an abundant immune cell population, with relatively few neoplastic Reed-Sternberg (RS) cells. These immune cells fail to initiate an anti-tumor response or prevent immune evasion. Both Lectin-like transcript 1 (LLT1) and CD161 are an immune checkpoint axis that modulates immune cells' responses in chronic infections, cancer, and autoimmune diseases. However, their expression within the HL TME is not well studied. Methods: This is a retrospective observational study that was conducted using archived formalin-fixed paraffin-embedded (FFPE) lymph node tissues from tertiary care center in Northern Jordan. A total of 56 HL cases and 60 reactive lymphoid tissue controls (benign lymph nodes and tonsils) were included. Immunohistochemistry (IHC) was performed to assess LLT1 and CD161 expression in background immune cells (BICs). The primary outcomes were the expression levels and localization patterns of LLT1 and CD161. Associations with clinicopathological variables were analyzed using Chi-square, Mann-Whitney U, Kruskal-Wallis, and Spearman correlation tests. Survival analysis was performed using the Kaplan-Meier method. Results: A significant correlation was observed between LLT1 and CD161 expression in the tumor microenvironment, both in the frequency of positive background immune cells) (BICs ( Conclusion: LLT1 and CD161 expression in HL BICs may suggest an immune-to-immune interaction within TME. CD161 enrichment in advanced disease and the mixed cellularity subtype highlights their potential role in sustaining immune recruitment and retention. Thus, LLT1 and CD161 expression patterns position them as potential targets for immunotherapy in HL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.